Hospital Universitari de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2024

  1. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  2. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

    Annals of Hematology

  3. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2023

  1. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Breakthrough infections in MPN-COVID vaccinated patients

    Blood Cancer Journal

  2. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  3. Second versus first wave of COVID-19 in patients with MPN

    Leukemia

  4. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

    Blood Cancer Journal, Vol. 11, Núm. 2

  2. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

    Leukemia, Vol. 35, Núm. 2, pp. 485-493

  3. Long-term follow-up of recovered MPN patients with COVID-19

    Blood Cancer Journal

  4. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy

    Biochemical Pharmacology, Vol. 192

2020

  1. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244

2018

  1. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia

    British Journal of Haematology

  2. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis

    Leukemia

  3. Prognostic risk models for transplant decision-making in myelofibrosis

    Annals of Hematology, Vol. 97, Núm. 5, pp. 813-820

2017

  1. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109